

Jose María Pelayo Terán

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2256080/publications.pdf>

Version: 2024-02-01

55
papers

2,010
citations

236925

25
h-index

243625

44
g-index

64
all docs

64
docs citations

64
times ranked

2851
citing authors

#	ARTICLE	IF	CITATIONS
1	Entire duration of active psychosis and neurocognitive performance in first-episode non-affective psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 1266-1275.	1.7	0
2	Mental health impact of the first wave of COVID-19 pandemic on Spanish healthcare workers: A large cross-sectional survey. <i>Revista De Psiquiatría Y Salud Mental</i> , 2021, 14, 90-105.	1.8	133
3	Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. <i>Journal of Psychiatric Research</i> , 2021, 134, 150-157.	3.1	7
4	Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. <i>European Neuropsychopharmacology</i> , 2021, 47, 74-85.	0.7	7
5	Development and validation of a questionnaire for assessing patients' perceptions of interprofessional integration in health care. <i>Journal of Interprofessional Care</i> , 2021, , 1-7.	1.7	0
6	Thirty-day suicidal thoughts and behaviors among hospital workers during the first wave of the Spain COVID-19 outbreak. <i>Depression and Anxiety</i> , 2021, 38, 528-544.	4.1	70
7	Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program. <i>Data in Brief</i> , 2020, 30, 105599.	1.0	0
8	Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 217-229.	2.1	40
9	Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study. <i>Schizophrenia Research</i> , 2020, 220, 240-247.	2.0	11
10	44 Real World Effectiveness: A 6-month Naturalistic Follow-up Study of Schizophrenia Patients After Switching to Aripiprazole Monohydrate (AOM) Treatment. <i>CNS Spectrums</i> , 2019, 24, 199-200.	1.2	1
11	Patterns of recovery course in early intervention for FIRST episode non-affective psychosis patients: The role of timing. <i>Schizophrenia Research</i> , 2019, 209, 245-254.	2.0	4
12	Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. <i>European Psychiatry</i> , 2018, 52, 29-37.	0.2	17
13	S124. RECOVERY TRAJECTORIES IN FIRST EPISODE PSYCHOSIS PATIENTS: THE ROLE OF TIMING. <i>Schizophrenia Bulletin</i> , 2018, 44, S373-S373.	4.3	0
14	S125. THE DYNAMIC RELATIONSHIP BETWEEN INSIGHT AND SUICIDAL BEHAVIOUR IN FIRST EPISODE PSYCHOSIS PATIENTS OVER 3-YEAR FOLLOW-UP. <i>Schizophrenia Bulletin</i> , 2018, 44, S374-S374.	4.3	2
15	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1090-1101.	2.1	16
16	The dynamic relationship between insight and suicidal behavior in first episode psychosis patients over 3-year follow-up. <i>European Neuropsychopharmacology</i> , 2018, 28, 1161-1172.	0.7	20
17	Seguridad en el uso de antidepresivos: hiponatremia inducida con vortioxetina a propósito de un caso. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 219-220.	1.8	7
18	Safety in the use of antidepressants: Vortioxetine-induce hyponatremia in a case report. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017, 10, 219-220.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 315-323.	3.2	32
20	Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. <i>Neurology and Therapy</i> , 2016, 5, 105-130.	3.2	22
21	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv132.	2.1	50
22	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
23	Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. <i>Psychological Medicine</i> , 2014, 44, 37-50.	4.5	37
24	Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. <i>Psychiatry Research</i> , 2013, 206, 181-187.	3.3	33
25	Evolución de la prevalencia administrativa de los trastornos mentales durante 13 años en Asturias (norte de España). <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 60-66.	1.8	8
26	Gene-Environment Interactions Underlying the Effect of Cannabis in First Episode Psychosis. <i>Current Pharmaceutical Design</i> , 2012, 18, 5024-5035.	1.9	48
27	Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. <i>Journal of Psychiatric Research</i> , 2012, 46, 1099-1105.	3.1	118
28	Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. <i>Psychopharmacology</i> , 2012, 219, 225-233.	3.1	24
29	Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. <i>Psychiatry Research</i> , 2011, 185, 286-289.	3.3	23
30	Insight dimensions in first-episode psychosis patients: clinical, cognitive, pre-morbid and socio-demographic correlates. <i>Microbial Biotechnology</i> , 2011, 5, 140-149.	1.7	31
31	Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. <i>Journal of Psychiatric Research</i> , 2011, 45, 763-769.	3.1	21
32	Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. <i>Journal of Psychopharmacology</i> , 2011, 25, 744-754.	4.0	15
33	EARLY RESPONSE TO ANTIPSYCHOTICS AS A MARKER OF TREATMENT RESPONSE OF PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 180.	2.0	2
34	Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. <i>Psychiatry Research</i> , 2010, 175, 189-194.	3.3	29
35	Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: Clinical-onset implications. <i>Psychiatry Research</i> , 2010, 179, 291-296.	3.3	46
36	Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. <i>Schizophrenia Research</i> , 2009, 107, 115-121.	2.0	83

#	ARTICLE	IF	CITATIONS
37	Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 550-556.	1.7	23
38	Epidemiological factors associated with treated incidence of first episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Microbial Biotechnology, 2008, 2, 178-187.	1.7	131
39	Interleukin-1 receptor antagonist genotype and brain morphometry in first-episode non-affective psychosis. Psychiatry Research - Neuroimaging, 2008, 162, 167-171.	1.8	5
40	Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population. Schizophrenia Research, 2008, 99, 13-22.	2.0	102
41	1-year follow-up study of cognitive function in first-episode non-affective psychosis. Schizophrenia Research, 2008, 104, 165-174.	2.0	42
42	Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: Effects of antipsychotic drugs. Psychiatry Research, 2008, 158, 206-216.	3.3	49
43	Effect of antipsychotic drugs on brain morphometry. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1936-1943.	4.8	46
44	P.3.a.002 Relationship between cannabis use and depression in a first episode of non-affective psychosis sample. European Neuropsychopharmacology, 2008, 18, S386.	0.7	0
45	Lack of influence of COMT Val158Met genotype on cognition in first-episode non-affective psychosis. Schizophrenia Research, 2008, 102, 206-209.	2.0	15
46	Pretreatment predictors of cognitive deficits in early psychosis. Psychological Medicine, 2008, 38, 737-746.	4.5	24
47	Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis. Psychological Medicine, 2008, 38, 1257-1266.	4.5	49
48	Effect of Antipsychotics on Peptides Involved in Energy Balance in Drug-Naive Psychotic Patients After 1 Year of Treatment. Journal of Clinical Psychopharmacology, 2008, 28, 289-295.	1.4	74
49	Low-activity allele of Catechol-O-Methyltransferase (COMT) is associated with increased lateral ventricles in patients with first episode non-affective psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1514-1518.	4.8	17
50	Reduced thalamic volume in first-episode non-affective psychosis: Correlations with clinical variables, symptomatology and cognitive functioning. NeuroImage, 2007, 35, 1613-1623.	4.2	66
51	Caudate nucleus volume and its clinical and cognitive correlations in first episode schizophrenia. Schizophrenia Research, 2007, 91, 87-96.	2.0	76
52	Predictors of acute treatment response in patients with a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research, 2007, 41, 659-666.	3.1	87
53	Cognitive dimensions in first-episode schizophrenia spectrum disorders. Journal of Psychiatric Research, 2007, 41, 968-977.	3.1	77
54	FC4E A PRACTICAL CLINICAL TRIAL COMPARING HALOPERIDOL, RISPERIDONE AND OLANZAPINE FOR THE ACUTE TREATMENT OF FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS. Schizophrenia Research, 2006, 86, S39.	2.0	2

#	ARTICLE	IF	CITATIONS
55	Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 939-943.	1.7	15